Merger Updates Between Pharmacosmos and G1 Therapeutics
Pharmacosmos A/S, a company based in Denmark known for its pioneering treatments for iron deficiency and iron deficiency anemia, along with G1 Therapeutics, Inc. (NASDAQ: GTHX), an oncology-focused organization committed to advancing cancer therapies, have recently announced important developments regarding their merger. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has officially concluded, allowing Pharmacosmos to move forward with its acquisition of G1 Therapeutics.
Details of the Merger Agreement
On August 7, 2024, the definitive merger agreement was established, stating that Pharmacosmos, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., intends to acquire all outstanding shares of G1 Therapeutics common stock for $7.15 per share in cash. This acquisition values G1 at around $405 million, reflecting a significant premium of 68% over G1’s closing share price just before the merger announcement.
Impact of the Expiration
The completion of the HSR waiting period signifies a crucial turning point for both companies as they prepare to execute the tender offer. However, this offer is still subject to standard closing conditions. One of the key requirements is that shareholders must tender shares representing at least a majority of the total outstanding shares of G1 Therapeutics.
Future Prospects for G1 Therapeutics
Unless the tender offer is extended, it is anticipated to expire shortly after 11:59 p.m. New York City time on September 17, 2024. This timeline is vital for G1 and its shareholders as it will dictate the speed at which the two companies can integrate their operations and resources.
Overview of Pharmacosmos Group
Established in 1965 and based in Holbaek, Denmark, Pharmacosmos A/S specializes in carbohydrate chemistry and is recognized globally for its innovative treatments addressing iron deficiency. With a strong presence in regions such as the UK, Ireland, Nordics, Germany, the USA, and China, the company prioritizes research and development to enhance its treatment options. Pharmacosmos employs over 500 individuals and boasts a unique carbohydrate production platform alongside deep expertise in synthesizing iron-carbohydrate complexes.
About G1 Therapeutics and Its Mission
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on improving the lives of cancer patients by developing next-generation therapies. With its first commercial product, COSELA (trilaciclib), G1 aims to deliver significant advancements in treatment. Located in Research Triangle Park, N.C., G1 is dedicated to maximizing therapeutic benefits for those fighting cancer.
Company Contacts
Contact for Pharmacosmos A/S:
Christian Lundquist Madsen
VP Global Marketing & Communication
+45 5948 5959
clm@pharmacosmos.com
Contact for G1 Therapeutics:
Will Roberts
Communications Officer, Vice President, Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com
Frequently Asked Questions
What is the current status of the merger between Pharmacosmos and G1 Therapeutics?
The merger is progressing as the Hart-Scott-Rodino waiting period has expired, allowing Pharmacosmos to proceed with acquiring G1 Therapeutics.
What is the purchase price per share in the proposed acquisition?
Pharmacosmos plans to acquire G1 Therapeutics at a cash price of $7.15 per share.
When is the expected deadline for the tender offer?
Unless extended, the tender offer is set to expire one minute after 11:59 p.m. New York City time on September 17, 2024.
How does this acquisition benefit Pharmacosmos?
This acquisition enables Pharmacosmos to expand its portfolio with G1 Therapeutics' cancer therapies and enhance its presence in the biopharmaceutical industry.
What are Pharmacosmos's primary areas of focus?
Pharmacosmos primarily concentrates on developing innovative treatments for iron deficiency and engages in extensive research in carbohydrate chemistry.
